Abstract: A pressurized container (1) for a viscous product, comprising a container body (2) with an opening (9), a piston (3), a dispensing closure (4) attached to the container body opening (9) which comprises closure walls, at least one dispensing aperture (13), at least one closing element (14) that is movable relative to the closure walls between a closed position and an open position, the container (1) further comprising a spring element (15) disposed between said closing element (14) and said closure walls, so as to naturally force the closing element (14) in a position where it closes said aperture (13), wherein the closure walls define a channel (16) with at least one lateral dispensing aperture (13) remote from the container body opening (9), said closing element (14) having the shape of a ring that seals around and is movable relative to the channel (16), by translation along, or by rotation around, an axis which is parallel to the longitudinal axis of the channel (16).

Abstract: The invention relates to quinazoline derivatives of formula (1) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group sele

Abstract: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3 (wherein R3 is piperidinyl-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR3 (wherein R3 is as defined hereinbefore); 3) C2-5alkynylR3 (wherein R3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Abstract: The invention concerns quinazoline derivatives of Formula (I), wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.

Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R1, R2, R3 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

Abstract: A pressurized receptacle that dispenses viscous product from a container that has a dispensing valve. The dispensing valve has a valve pot that is secured in the container opening which seats a spring that biases a dispensing stack and a valve element to a closed position. The biasing position can be selectively overcome by a rotary collar that interacts with a helical ramp that can house at least one stud that drives the dispensing stack and thereby the valve element open to allow dispensation to occur.

Abstract: The present invention provides a thin film photovoltaic module that has a protective substrate, such as glass, that has been contoured to define a space that allows air to avoid entrapment by a bus bar on the thin film photovoltaic device. The contouring of the protective substrate greatly facilitates the deairing and lamination of the module because it reduces or eliminates the amount of trapped air during lamination. Photovoltaic modules of the present invention can be processed with a minimum of waste caused by deairing and related lamination problems.

Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.

Abstract: Glass laminates are prepared using low-water content plastic interlayer material, such as polyvinylbutyral interlayer sheets, by a process employing nip roll de-airing, and high temperature finishing at atmospheric pressure.

Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R1, R2, R3 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease.

Abstract: The present invention provides a thin film photovoltaic module that has a protective substrate, such as glass, that has been contoured to define a space that overlies a bus bar on the thin film photovoltaic device. The contouring of the protective substrate greatly facilitates the deairing and lamination of the module because it reduces or eliminates the amount of trapped air and the degree to which the underlying polymeric material is forced to flow during lamination. Photovoltaic modules of the present invention can be processed with a minimum of waste caused by deairing and related lamination problems.

Abstract: The invention concerns quinazoline derivatives of the formula: (I); wherein X1, Q1, Z, R1, R2, Y, a and m are as defined in the description, which are erbB tyrosine kinase inhibitors, particularly EGFR tyrosine kinase inhibitors. Also claimed are processes for their preparation; pharmaceutical compositions containing them; and their use as therapeutic agents in the treatment of erbB tyrosine kinase mediated diseases such as cancer.

Abstract: The invention concerns quinazoline derivatives of the Formula I: wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

Abstract: A quinazoline derivative of the formula I: wherein: R1, R2, R3, R3a, R4, R5, R5a R6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula I, are useful in the treatment of hyperproliferative disorders such as a cancer.

Abstract: The present invention provides a thin film photovoltaic device comprising a poly(vinyl butyral) layer that provides excellent adhesion, resistivity, sealing, processability, and durability to the device.

Abstract: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.

Abstract: A container (1) comprising a container body (2) and a dispensing closure (4), the closure comprising walls (5), at least one dispensing aperture (6), at least one closing element (7) that is movable between a position where said aperture is closed, and a position where the aperture is open, said closure further comprising at least one actionable means (8) that surrounds the closure walls and the closing element.

Abstract: A dispensing closure for a container that includes closure walls, at least one dispensing aperture, at least one closing element that is movable between a position where the aperture is closed, and a position where the aperture is open. This closure includes at least one actionable member that surrounds the closure walls and the closing element, and at least one connection element located between the actionable member and the closing element. The connection element is made of a material that is sufficiently rigid below a predetermined safety temperature, to connect the actionable member and closing element, thus allowing opening of the dispensing aperture by moving the actionable member and fluid above temperature so that the actionable member and closing element are disconnected.

Abstract: The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

Abstract: The invention relates to quinazoline derivatives of formula (1) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group sele